ASPEN PHARMACARE HOLDINGS LIMITED - No Change Statement and Notice of Annual General Meeting 9 December 2020

No Change Statement and Notice of Annual General Meeting – 9 December 2020

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)



NO CHANGE STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING – 9 DECEMBER 2020


1. POSTING OF AGM NOTICE AND ABBREVIATED REPORT

Shareholders are advised that the Company’s Integrated Report for the year ended 30 June 2020 has
been finalised and that the abbreviated report and the notice of the annual general meeting (“AGM”)
to be held at its Durban offices on 9 December 2020 is being posted to shareholders. The following
documents have been posted online at the Company’s website www.aspenpharma.com (at the
following link https://www.aspenpharma.com/investor-information/):

    - Integrated Report for the 2020 financial year; Notice of AGM and proxy in respect of the AGM
      to be held on 9 December 2020;
    - Unabridged Corporate Governance Statement and reports of the Aspen Audit & Risk and Social
      & Ethics committees for the 2020 financial year;
    - Annual Financial Statements for the 2020 financial year (“AFS”); and
    - Various other reports supplementary to the Integrated Report.

 The AFS contain no modifications to the reviewed provisional results which were published on
 SENS on 9 September 2020. The AFS were audited by PricewaterhouseCoopers Inc. Their
 unqualified report, along with an originally signed copy of the AFS, is available for inspection at
 the Company’s registered office.

 2. NOTICE OF AGM

 Notice is hereby given that the 22nd annual general meeting of the shareholders of the Company will
 be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban,
 Kwa-Zulu Natal, on Wednesday, 9 December 2020 at 10:00. Should you choose to attend the meeting
 in person, please ensure that you contact the Company Secretary & Group Governance Officer at
 rverster@aspenpharma.com / 031 580 8624 by no later than 10:00 on Monday, 7 December 2020 in
 order to ensure compliance with COVID-19 regulations and requirements.

 The record date on which a person must be registered as a shareholder in the register of the Company
 for purposes of being entitled to attend and participate in, and speak and vote at, the meeting is
 Friday, 27 November 2020. Accordingly, the last day to trade in order to be registered in the register of
 members of the Company and therefore be eligible to participate in and vote at the annual general
 meeting is Tuesday, 24 November 2020. Shareholders are requested, but are not obliged, to submit
 their completed forms of proxy to the Company’s transfer secretaries (Link Market Services) before
 10:00 on Monday, 7 December 2020.
 Shareholders who, for whatever reason, experience postal delays and who do not receive the
 notice of the AGM in time to submit proxy forms to the Company’s share transfer secretaries (Link
 Market Services) are requested to access the notice of AGM and other documents referred to
 above on the Company’s website www.aspenpharma.com. A printable version of these
 documents in PDF format can also be emailed to shareholders upon request to the Company
 Secretary – rverster@aspenpharma.com or +27 31 580 8624.

 Electronic participation
 Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by
 way of telephone/ video conference call, and if they wish to do so:
 • Must contact the Company Secretary & Group Governance Officer (by email at the address
   rverster@aspenpharma.com) by no later than 10:00 on Friday 27 November 2020 in order to
   obtain the dial-in details / meeting link in order to participate in the meeting;
 • Will be required to provide reasonably satisfactory identification; and
 • Will be billed separately by their own service providers for the costs incurred in respect of their
   telephone/ video call to participate in the meeting.

3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE

Shareholders are hereby notified that in accordance with the JSE Listings Requirements, the
Company's B-BBEE compliance report in terms of section 13G(2) of the Broad-Based Black Economic
Empowerment Act 53 of 2003 read with the Broad-Based Black Economic Empowerment Act 46 of
2013, is in the process of being submitted to the BEE Commission and will be made available on the
Company’s website www.aspenpharma.com as soon as the submission process has completed. A
further announcement in this regard will be made to shareholders.

Durban
28 October 2020

Sponsor
Investec Bank Limited

Date: 28-10-2020 05:50:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.